Skip to content
NeuroTechGuide

Synchron pauses enrollment in its next-generation Stentrode trials over a lead problem

The endovascular BCI company stopped recruiting in its US, Australian and Canadian studies after a performance issue with the implant's lead, and is restructuring around a new San Diego team.

1 min readImplantsClinical trialsIndustry

Synchron, the company behind the blood-vessel-delivered Stentrode brain-computer interface, has voluntarily paused enrollment in the clinical trials of its second-generation device after it did not perform as expected in early participants. WIRED first reported the pause on November 12; STAT and Inside BCI followed on November 13. The company attributes the problem to “a performance issue involving the lead,” the cable that carries signals from the Stentrode to the implanted electronics.

What we know

Synchron says the Stentrode itself is not the problem, that it has found no device-related safety issues, and that the FDA did not order the pause. It has moved lead design and manufacturing in-house and plans to upgrade the whole system before recruitment restarts. No restart date has been given.

According to Inside BCI, the affected studies are INTENT in the US (target 10 participants at five sites) and FOCUS-AUS at the Royal Melbourne Hospital (target 10), both now listed as active but not recruiting. A Canadian study, FOCUS-CAN, is listed as terminated with one participant enrolled, citing insufficient recruitment; Synchron has not said whether that is related. WIRED also reported job cuts and a smaller New York presence while the company builds a team in San Diego to make the upgraded lead and Stentrode. The number of jobs affected has not been disclosed.

Why it matters

  • Synchron’s endovascular approach avoids open-brain surgery and was among the most advanced US BCI programs. It raised a $200 million Series D a year ago.
  • The pause will likely delay a pivotal trial and an eventual FDA submission. The company has not said how its plans have changed.
  • Synchron says it will keep supporting people who already have the device. The first-generation Stentrode was implanted in ten people in the US and Australia.

Learn more: Endovascular BCI · Clinical trial pathway · Synchron in the Directory

Share:XLinkedInBlueskyEmail

More news